Earnings Play: Agilent Technologies
Jason Lubin November 21, 2020 12:10 AM
Upside breakout from a short-term falling wedge pattern.
On Monday, after market, Agilent Technologies (A) is anticipated to release fourth quarter EPS of $0.92 compared to $0.89 a year ago on revenue of approximately $1.4 billion, in line with last year. Agilent is an international life sciences and diagnostics company, and on November 13th, the Co announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of its PD-L1 IHC 22C3 pharmDx as a diagnostic aid in the identification of triple-negative breast cancer and other conditions.
Technically speaking, on a daily chart, Agilent's stock price has been in a strong uptrend since mid-March. Today, price opened above the upper trendline of a short-term falling wedge pattern that price has been declining within since November 9th, after the stock made a record high of 117.50. The simple moving averages (SMA) are set-up in a bullish manner, with the 20-day SMA above the 50-day SMA and the 50-day SMA above the 200-day SMA. The RSI is over 50 and pointing upwards. Price will likely advance towards its all-time high of 117.50. If price can breakout to the upside of 117.50, then its next target would be 132.75. If price retreats then investors should look for a rebound off of 100.50. If price breaks out below 100.50 it would be a bearish signal that could send price tumbling back to 93.00.
Source: GAIN Capital, TradingView
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.
Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.